ReviewCancers2026
Endometrial Cancer Related to Endometrial Ablation: A Narrative Review.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent post-endometrial ablation uterine bleeding indicates that no method of EA eliminates the entire endometrium, and post-EA hysteroscopy shows a distorted and scarred uterine cavity in the majority of patients. These observations raise concerns regarding presentation, assessment and stage of potential post-ablation endometrial cancer (PAEC), developing in residual endometrium pockets. To better understand these concerns, a literature search was conducted, from the introduction of EA in the 1980s through 2025, to capture reports of endometrial cancer (EC) associated with or following EA using multiple data bases, imputing search terms of EC following EA and possible combinations of first- and second-generation EA techniques associated with EC. Upon review of all publications, we identified 86 ECs associated with EA, described in 20 case reports (N = 20), four case series (N = 18), eleven cohort studies (N = 21), one registry (N = 27) and five reviews. Based on 12 relevant studies at a median follow-up of 8.5 years (range 1.9-25), 43 EC were identified in 39,795 women with a history of EA, with a summary incidence of 0.11% (range 0.0-1.59%). Although the studies and data are very heterogeneous, it appears that EA may afford a protective effect in reducing the risk of EC in the short term. The mechanistic effect is likely due to a quantitative reduction in the endometrium that can potentially become malignant, and/or due to the elimination of occult pre- or malignant endometrial elements which are vulnerable to EA. Moreover, based on 25 evaluable cases, the mode and time to presentation, the diagnostic work-up (including endometrial biopsy and hysteroscopy), and the stage of PAEC appear not to be altered by EA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.